- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01888354
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
September 14, 2014 updated by: Staley Brod, The University of Texas Health Science Center, Houston
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
This pilot study is designed as a prospective cohort study to determine whether standard subcutaneous (SQ) Highly-Purified (HP) Acthar Gel 14 days is superior to SQ HP Acthar Gel 5 days in the treatment of relapses or attacks in multiple sclerosis (MS).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Evaluations and treatment will be administered as an outpatient in the Neurology Clinic.
Each subject will be seen for MS relapse or exacerbation in the Neurology Clinic during a routine or semi-emergent visit.
Patients will be offered an FDA approved treatment (ACTHar Gel) for MS attacks under a standard 14 day SQ protocol (standard 14 day SQ protocol (80 IU x 14 days) or a 5 day SQ protocol - (5 day subcutaneous protocol (80 IU x 5 days).
Both protocols are within package insert guidelines.
The subjects will be evaluated for Extended Disability Status Scales (EDSS), a standardized measure of clinical status in MS and the initial visit and 28 days later (and 90 days later).
We will compare the change in EDSS outcomes between day 0 and day 28 (day 90) to determine if the 14 days is superior to 5 day protocol may be clinically equivalent.
Patients will also be evaluated for walking, upper extremity function (9 hole peg test), cognition and vision.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Oceanside, California, United States, 92056
- The MS Center at the Neurology Center in Southern California
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas-Houston Neurology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult male or female subjects with MS having a relapse (attack) or exacerbation of MS. Acute symptomatic exacerbation of MS present for > 24 hours and < 14 days at screening with new or worsening symptoms, and with signs referable to the symptoms in the absence of a fever or active infection.
- Diagnosis of a relapsing forms of multiple sclerosis before randomization as determined by Poser or McDonald Criteria (standard MS diagnostic criteria).
- Expanded disability status scale (EDDS) between 2 and 6.5, inclusive at entry.
- Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.
- New objective clinical finding other than the sensory exacerbation or the bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.
- Subjects may continue on their current immunomodulation therapy such as interferons, glatiramer acetate, gilenya or natalizumab.
- Identified patients must be between the ages of 18 and 55 years, inclusive.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Subjects who are pregnant, or nursing.
- Any patients treated with systemic corticosteroid use within one month of the index episode at screening.
- Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, Cellcept, IVIg) or plasmapheresis.
- Unable to perform timed 25 foot walk (ambulation Index), 9 HPT (9 hole peg test), PASAT (Paced Auditory Serial Addition Test) 3.
- Peripheral or cranial neuropathy as sole problem of acute episode.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy.
- Subjects with clinical diagnosis of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, hypertension, or sensitivity to proteins of porcine origin.
- Primary Progressive Multiple Sclerosis (PPMS) (MS without attacks). -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acthar Gel 80 IU x 14 days
Acthar Gel 80 IU SQ x 14 days
|
Acthar Gel 80 IU
Other Names:
|
Experimental: Acthar Gel 80 IU x 5 days
Acthar Gel 80 IU SQ x 5 days
|
Acthar Gel 80 IU
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of EDSS Mean Recovery between 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 Days (with 90 day follow-up)
|
To determine whether a standard 14 day course of SQ 80 IU ACTHar Gel therapy might be superior (in twice as many patients) to treatment with 5 day SQ regimen for ACTHar Gel as determined by EDSS mean recovery from Day 0 (time of steroid therapy initiation) to Day 28 (and day 90).
|
28 Days (with 90 day follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of ambulation between the 5-day vs.14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 Days (with 90 day follow-up)
|
The ambulation index (AI) will be used for patients with long track (pyramidal) relapses, i.e. relapses with leg involvement.
This is a standardized rating scale developed to assess mobility by evaluating the time and degree of assistance required to walk 25 feet.
|
28 Days (with 90 day follow-up)
|
Comparison of upper extremity function between the 5-day vs.14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 day (with 90 follow up)
|
The nine-hole peg test (9HPT) will be used for patients with arm involvement during relapses.
The 9-HPT is a brief, standardized, quantitative test of upper extremity function.
This is a timed test to determine how long it takes the patient to quickly place nine pegs (one at a time) in a wooden box with 9 empty holes, and them remove them again (one at a time) as quickly as possible.
Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand.
|
28 day (with 90 follow up)
|
Comparison of subjective impressions of effectiveness between the 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 day (with 90 day follow up)
|
The patient global impression of change (PGI-Change) will be used in patients to compare subjective impressions of effectiveness between treatment groups
|
28 day (with 90 day follow up)
|
Compare visual function between 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 day (with 90 day follow up)
|
Visual function, as measured by low contrast Sloan sensitivity testing (LCSST) will be performed on each patient at baseline and at the end of treatment
|
28 day (with 90 day follow up)
|
Comparison of cognitive function between the 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups
Time Frame: 28 day (with 90 day follow up)
|
In patients who report cognitive deficits during relapse, the paced auditory serial addition test (PASAT-3) will be used to assess and measure capacity and rate of information processing, and sustained and divided attention.
This is a common neuropsychological test used in MS trials that involves working memory, attention and arithmetic capabilities.
Patients will hear a series of recorded single-digit numbers at a rate of 1 per 3 seconds, and asked to add the number they just heard with the number they heard before.
|
28 day (with 90 day follow up)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of MRI brain activity before and after ACTH treatment between the two treatment groups
Time Frame: 28 Days (with 90 day follow-up)
|
Brain MRI scan ± Gd will be performed on subjects at entry, day 28 and day 90.
Qualitative assessments of changes in numbers of Gd+ lesions from entry to exit will be assessed.
|
28 Days (with 90 day follow-up)
|
Comparison of immune changes before and after ACTH treatment between the two treatment groups
Time Frame: 28 Days (with 90 day follow-up)
|
Peripheral mononuclear cells will be collected from patients at baseline,14 and 28 days post treatment and cytokine responses will be examined using a customized Human Cytokine Inflammatory Antibody Array including Th1-like (IL-2, IL-17, IFN-g, TNF-a, IL-1b), Th2-like cytokines (IL-4, IL-10, IL-13)
|
28 Days (with 90 day follow-up)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Staley A. Brod, MD, The Universtiy of Texas-Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
August 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
May 16, 2013
First Submitted That Met QC Criteria
June 24, 2013
First Posted (Estimate)
June 27, 2013
Study Record Updates
Last Update Posted (Estimate)
September 16, 2014
Last Update Submitted That Met QC Criteria
September 14, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenocorticotropic Hormone
Other Study ID Numbers
- HSC-MS-12-0210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis (MS)
-
Association de Recherche Bibliographique pour les...Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse GraceCompletedHealthy | Clinically Isolated Syndrome | Multiple Sclerosis (MS) | Radiologically Isolated Syndrome | Multiple Sclerosis (MS) Relapsing Remitting | Multiple Sclerosis (MS) Primary Progressive | Multiple Sclerosis (MS) Secondary ProgressiveMonaco
-
GeNeuro Innovation SASCompletedMultiple Sclerosis (MS) | Clinically Isolated Syndrome (CIS) | Secondary Progressive MS | Primary Progressive MS | Relapsing-Remitting MSFrance, Spain, Switzerland
-
Dimitrios KarussisCompletedMultiple Sclerosis (MS)Israel
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
Anokion SAActive, not recruitingRelapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)United States
-
University Hospital, Basel, SwitzerlandFreie Akademische Gesellschaft BaselRecruitingMultiple Sclerosis (MS)Switzerland
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedMultiple Sclerosis (MS)United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
-
Nermin ÇalışırBursa Sevket Yilmaz Training and Research HospitalActive, not recruitingMS (Multiple Sclerosis)Turkey
-
Fondazione Italiana Sclerosi MultiplaOpera CRO, a TIGERMED Group CompanyUnknownMS (Multiple Sclerosis)Italy, Romania
-
Assistance Publique - Hôpitaux de ParisUnknownMultiple Sclerosis (MS)France
Clinical Trials on H.P. Acthar Gel (repository corticotropin injection)
-
MallinckrodtCompletedDiabetic NephropathyUnited States
-
The Cleveland ClinicMallinckrodtCompletedPanuveitis | Anterior Uveitis | Ocular SarcoidosisUnited States
-
Dent Neuroscience Research CenterCompletedChronic MigraineUnited States
-
MallinckrodtCompleted
-
Mamatha Pasnoor, MDMallinckrodtWithdrawnChronic Inflammatory Demyelinating PolyneuropathyUnited States
-
MallinckrodtCompletedAmyotrophic Lateral SclerosisUnited States
-
MallinckrodtWithdrawnAcute Respiratory Distress Syndrome
-
Ronald J. Rapoport, MDMallinckrodtUnknownRheumatoid ArthritisUnited States
-
The Cleveland ClinicMallinckrodtWithdrawn
-
MallinckrodtCompletedProteinuria | Idiopathic Membranous NephropathyUnited States, Canada, Chile, Mexico, Turkey